Authors' reply to Tufan and colleagues and Boucaud-Maitre

BMJ. 2016 Jun 7;353:i3188. doi: 10.1136/bmj.i3188.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / administration & dosage
  • Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
  • Drug Therapy, Combination
  • Humans
  • Hypoglycemia* / chemically induced
  • Hypoglycemia* / prevention & control
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Meta-Analysis as Topic
  • Patient Selection
  • Research Design
  • Risk Adjustment
  • Sulfonylurea Compounds* / administration & dosage
  • Sulfonylurea Compounds* / adverse effects

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Sulfonylurea Compounds